Two high-tech enterprises completed financing at the beginning of the year.

Starting the year with a rush, recently, two high-tech enterprises in the new district officially announced the completion of a new round of financing. They have achieved “accelerated progress” in the two key sectors of semiconductor core equipment and innovative pet drugs.
One is Nanjing Yili Chengchuang Semiconductor Technology Co., Ltd. (referred to as “Yili Chengchuang”), which specializes in “invisible bubbles” in chip packaging. The other is Nanjing Patemei Sheng Technology Co., Ltd. (referred to as “Patemei Sheng”), which aspires to bring Chinese pet drugs to the global market. Their stories feature both cutting-edge technological breakthroughs and warm entrepreneurial intentions.

Yili Xinchuang removes “bubbles” from chips and has received capital support.

Recently, Yili Xinchuang announced the completion of its A+ round of financing. This round was jointly invested by Chengchen Venture Capital and Diankong Investment.
This company, founded in 2021, is dedicated to one thing: removing “bubbles” from chips. You should know that in this microscopic world of chips, “bubbles” are the “invisible killers”. Even a single bubble as small as a micrometer in a thin chip can cause the entire chip to be scrapped.
Yili Xinchuang, relying on two core technologies – heat flow and air pressure, has developed the degassing system and the wafer-level vacuum lamination film system. It has become an essential component in advanced packaging processes.

It is particularly worth mentioning that the company’s self-developed wafer-level vacuum lamination film system innovatively adopts the “vacuum lamination + soft pad airbag pressing” solution, which can achieve the industry-leading 1:20 high-depth-to-width ratio filling effect and perfectly cope with the challenges of unevenly textured wafers.

Yili Xinchuang’s strength comes from two industry veterans – Chairman Wei Xiaobing and General Manager Zhang Jingnan. Zhang Jingnan has led key projects such as the IGBT packaging transformation in Japan. He has a profound technical foundation. Currently, the company has established three technical support platforms in Nanjing, Taiwan of China, and Tokyo of Japan. Its products have not only passed the rigorous verification of leading domestic enterprises, but also successfully delivered to a leading communication enterprise in Malaysia in 2025, setting sail for the international market.

Patemei Sun has made “Chinese medicine” protect the “little creatures” all over the world.

Pets are an integral part of our families. However, when they fall ill, most of the medicines available are imported from overseas. Currently, the domestic rate of pet medication self-production is less than 10%. There is a huge market gap waiting to be filled.
Patemei Sheng has emerged precisely in this vast market. Recently, the company successfully completed a new round of financing, with participating institutions including Qinzhi Capital. It is worth noting that this is the second time that Patemei Sheng has received capital favor within less than three years of its establishment.

Li Yi, the founder of Patemei Sheng, also holds another identity – a member of the founding team of Yao Shi Technology. Crossing from the field of human medication to the pet medication sector, there is a touching story behind it. In the early days, a Chinese farm dog named “Dahuang” that Li Yi had raised suddenly died due to illness, which made him feel deeply regretful.
“Whether it’s developing drugs for humans or pets, we are all striving to hold on to our care and concern,” Li Yi once said. With this Original intention， in 2023， he founded Patemei Sheng， relying on the strong R&D background of shareholders such as Yao Shi Technology and Yaokang Biology， and committed to building the first high-standard one-stop pet health innovation technology service platform in the country.

Currently, the company is conducting over 10 research projects, among which there are 4 target first-class innovative drug projects. Its R&D capabilities rank among the top in the industry. With the Chinese pet economy surpassing the 100-billion-yuan mark, Patemaisun is striving to ensure that pet medicines made in China can protect the “pets” all over the world.
From overcoming “critical” hard technologies to providing comforting medicines for life, the innovative ecosystem in Jiangbei New District is nurturing an increasing number of distinctive “seed competitors”.
Let’s give a round of applause to these two enterprises and look forward to more enterprises in the new district achieving a faster development pace.